BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAE - Trial NCT06247865
Access comprehensive clinical trial information for NCT06247865 through Pure Global AI's free database. This phase not specified trial is sponsored by Portsmouth Hospitals NHS Trust and is currently Not yet recruiting. The study focuses on Neoplasms. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Portsmouth Hospitals NHS Trust
Timeline & Enrollment
N/A
Mar 01, 2024
May 01, 2025
Primary Outcome
Prediction of patient risk of irAE.
Summary
The study will collect leftover clinic blood samples on new oncology ICPI patients and test
 them for routine blood tests and malondialdehyde. Malondialdehyde can assess the body's
 oxidative stress level, a condition where your body lacks antioxidants. The NHS does not
 offer a malondialdehyde test presently, the study would produce a new NHS blood test. Once
 testing is completed the samples will be destroyed. Blood test results will be correlated to
 the patient's outcome i.e., did they have an irAE and assess if there are any differences in
 the results. From this information, the investigators hope to understand which blood tests
 help to highlight if a patient is at risk of developing irAE before it occurs.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06247865
Non-Device Trial